Loading...
Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis
BACKGROUND: Budesonide multimatrix (MMX) system has been approved for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), and offers potential safety benefits over more commonly utilized corticosteroid therapies. OBJECTIVES: In a real-world setting we aimed...
Na minha lista:
| Udgivet i: | Inflamm Intest Dis |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger AG
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6751477/ https://ncbi.nlm.nih.gov/pubmed/31559263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501004 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|